NMD4C Welcomes Two New Staff Members

The NMD4C recently welcomed two new members to the network coordination team! Marine Christin, PhD joins us as the new Pre-Clinical Science Coordinator, and Maria Masnata, PhD joins as the Clinical Trials and Community of Practice Manager. 

 

Marine Christin, PhD | Pre-Clinical Science Coordinator

 

Marine Christin

After graduating with a BSc and an MSc in Pharmacology, Physiology, and Neurobiology, Marine Christin obtained her Ph.D. in Cellular and Molecular Interactions from Nice Sophia-Antipolis University. During her postdoctoral fellowship at McGill University, her research focused on investigating the role of ion channels in pain. Currently serving as the Program Manager for the McGill Regenerative Medicine Network, she oversees and coordinates research and educational activities within the Network.  

Within the NMD4C, Marine oversees the coordination of the animal and cell-based research activities, including the basic research summer school. 

 

Maria Masnata, PhD | Clinical Trials and Community of Practice Manager

 

Dr Maria Masnata, Clinical Trials and Community Practice Manager.Maria has over 10 years of experience in clinical and in preclinical research in the field of the Neurosciences. She received her M.Sc. in Pharmacy from University of Cagliari in 2015 and her Ph.D. in Neurobiology from Université Laval in 2021. Maria developed extensive experience in clinical research and project management during her previous role as the Assistant Manager of the Investigator-Initiated Trial team of the Clinical Research Unit at The Montreal Neurological Institute/Hospital (McGill University).  

With a proven track record of managing and coordinating projects leading to Health Canada-approved clinical trials, peer-reviewed publications and national/international presentations, Maria is committed to advancing healthcare and advocating for scientific innovation in her role as Clinical Trials and Community of Practice Manager. 

NMD4C welcomes two new staff members - Marine Christin, PhD and Maria Masnata, PhD

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.